A comparison of self-report and antiretroviral detection to inform estimates of antiretroviral therapy coverage, viral load suppression and HIV incidence in Kwazulu-Natal, South Africa
Open Access
- 29 September 2017
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 17 (1) , 653
Abstract
Accurately identifying individuals who are on antiretroviral therapy (ART) is important to determine ART coverage and proportion on ART who are virally suppressed. ART is also included in recent infection testing algorithms used to estimate incidence. We compared estimates of ART coverage, viral load suppression rates and HIV incidence using ART self-report and detection of antiretroviral (ARV) drugs and we identified factors associated with discordance between the methods. Cross-sectional population-based survey in KwaZulu-Natal, South Africa. Individuals 15–59 years were eligible. Interviews included questions about ARV use. Rapid HIV testing was performed at the participants’ home. Blood specimens were collected for ARV detection, LAg-Avidity HIV incidence testing and viral load quantification in HIV-positive individuals. Multivariate logistic regression models were used to identify socio-demographic covariates associated with discordance between self-reported ART and ARV detection. Of the 5649 individuals surveyed, 1423 were HIV-positive. Median age was 34 years and 76.3% were women. ART coverage was estimated at 51.4% (95%CI:48.5–54.3), 53.1% (95%CI:50.2–55.9) and 56.1% (95%CI:53.5–58.8) using self-reported ART, ARV detection and both methods combined (classified as ART exposed if ARV detected and/or ART reported) respectively. ART coverage estimates using the 3 methods were fairly similar within sex and age categories except in individuals aged 15–19 years: 33.3% (95%CI:23.3–45.2), 33.8% (95%CI:23.9–45.4%) and 44.3% (95%CI:39.3–46.7) using self-reported ART, ARV detection and both methods combined. Viral suppression below 1000cp/mL in individuals on ART was estimated at 89.8% (95%CI:87.3–91.9), 93.1% (95%CI:91.0–94.8) and 88.7% (95%CI:86.2–90.7) using self-reported ART, ARV detection and both methods combined respectively. HIV incidence was estimated at 1.4 (95%CI:0.8–2.0) new cases/100 person-years when employing no measure of ARV use, 1.1/100PY (95%CI:0.6–1.7) using self-reported ART, and 1.2/100PY (95%CI:0.7–1.7) using ARV detection. In multivariate analyses, individuals aged 15–19 years had a higher risk of discordance on measures of ARV exposure (aOR:9.4; 95%CI:3.9–22.8), while migrants had a lower risk (aOR:0.3; 95%CI:0.1–0.6). In KwaZulu-Natal, the method of identifying ARV use had little impact on estimates of ART coverage, viral suppression rate and HIV incidence. However, discordant results were more common in younger individuals. This may skew estimates of ART coverage and viral suppression, particularly in adolescent surveys.Keywords
Funding Information
- Médecins Sans Frontières
- National Institutes of Health
This publication has 11 references indexed in Scilit:
- Who Needs to Be Targeted for HIV Testing and Treatment in KwaZulu-Natal? Results From a Population-Based SurveyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2016
- Detectable HIV Viral Load in Kenya: Data from a Population-Based SurveyPLOS ONE, 2016
- Closer to 90–90–90. The cascade of care after 10 years of ART scale‐up in rural Malawi: a population studyJournal of the International AIDS Society, 2016
- Antiretroviral Treatment Scale-up Among Persons Living With HIV in KenyaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2014
- Recent Patterns in Population-Based HIV Prevalence in SwazilandPLOS ONE, 2013
- Community Viral Load and CD4 Count Distribution Among People Living With HIV in a South African TownshipJAIDS Journal of Acquired Immune Deficiency Syndromes, 2013
- Tenofovir, Emtricitabine Intracellular and Plasma, and Efavirenz Plasma Concentration Decay Following Drug Intake CessationJAIDS Journal of Acquired Immune Deficiency Syndromes, 2013
- A New General Biomarker-based Incidence EstimatorEpidemiology, 2012
- Pharmacokinetics of Atazanavir/Ritonavir Once Daily and Lopinavir/Ritonavir Twice and once Daily over 72 h following drug CessationAntiviral Therapy, 2008
- Clinical implications of stopping nevirapine‐based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistanceHIV Medicine, 2004